type here...

CATEGORIES

Medication

LATEST

1234Page 2 of 4

TRENDING

EDITORS CHOICE

New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey

Medika Life -
Respondents Reported Physical and Psychosocial Impacts of Living with Bipolar I Disorder and Side Effects of Medications Used to Treat the Disease More Than...

Achieve Life Sciences Announces Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers

Medika Life -
Clinical results in primary and secondary endpoints for 6- and 12-week experimental smoking cessation treatment reported by company sponsor.

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

Medika Life -
SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

Once-Resistant Rural Court Officials Begin to Embrace Medications to Treat Addiction

Medika Life -
DANDRIDGE, Tenn. — Rachel Solomon and judges hadn’t been on the best of terms. Then Judge O. Duane Slone “dumbfounded” her. Solomon was given...

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories